medigraphic.com
ISSN 1560-4381 (Print)

2015, Number 2

<< Back Next >>

Correo Científico Médico 2015; 19 (2)

High sensitivity C reactive protein and cardiovascular disease risk

Vega AJ, Guimará MMR, Garces HY, García BY, Vega ALA

Language: Spanish
References: 25
Page: 190-201
PDF size: 300.84 Kb.


ABSTRACT

Introduction: C reactive protein is a non specific marker of inflammation and a predictor of incident coronary heart disease, cardiovascular disease and subclinical vascular disease.
Objective: to expose the roll of high sensitivity C reactive protein in the prediction of cardiovascular risk.
Methods: a cross sectional survey was carried out, the population were 1 200 patients with age between 34-75 years old without cardiovascular disease of the Velasco Teaching Polyclinic during January to June 2011, the random sample were 168 participants, whom had available c reactive protein test, the cardiovascular risk was stratified through the determination of high sensitivity C reactive protein and compared with the coronary and global cardiovascular risk calculated by the Framingham-Wilson risk score and the Framingham-D´Agostino risk score respectively, the correlation coefficient among high sensitivity C reactive protein and the cardiovascular risk was calculated.
Results: mean age 52.4 ± 12.5 years, 65 % women. The mean of high sensitivity c reactive protein was 2.81 ± 2.60 mg/L, the correlation coefficient between level of high sensitivity C reactive protein and cardiovascular risk calculated was 0.275 (p 0.023) for coronary heart disease risk and 0.292 (p 0.013) for global cardiovascular risk. When re-stratified the cardiovascular risk calculated according to the risk obtained by means of high sensitivity C reactive protein concentration, 15.7 % of participants were reclassified as intermediate risk and the 5.1 % as high risk.
Conclusions: the high sensitivity C reactive protein determination is useful in the preventive decision making due to its contribution to improve the prediction of cardiovascular risk calculated with the specific risk table.


REFERENCES

  1. Charakida M, Masi S, Deanfield JE. The Year in Cardiology 2012: focus on cardiovascular disease prevention. Eur Heart J. 2013 [citado 21 nov 2014]; 34: 314–7. Disponible en: http://eurheartj.oxfordjournals.org/content/ehj/early/2013/01/02/eurheartj.ehs429.full.pdf

  2. Tarragó E, Miguel Soca PE, Cruz L, Santiesteban Y. Factores de riesgo y prevención de la cardiopatía isquémica. CCM. 2012 [citado 20 nov 2014]; 16(2). Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/505

  3. Cuba. Ministerio de salud Pública. Anuario estadístico de salud en Cuba. La Habana. MINSAP; 2010. [citado 2 abr 2013]. Disponible en: http://files.sld.cu/dne/files/2011/04/anuario-2010-e-sin-graficos1.pdf

  4. Miguel Soca PE, Niño Escofet S, Rodríguez López M, Almaguer Herrera A. Pesquisaje de síndrome metabólico en mujeres obesas. CCM. 2004 [citado 7 jul 2013]; 8(4). Disponible en: http://www.cocmed.sld.cu/no84/n84ori5.htm

  5. Dhingra R, Philimon G, Byung Ho N, D’Agostino RB, Wilson PW, Benjamin EJ, et al. C - reactive protein, inflammatory conditions and cardiovascular disease risk. Am J Med. 2007 [citado 7 jul 2013]; 120(12): 1054–62. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2215387/

  6. Nordet P, Mendis M, Dueñas A, de la Noval R, Armas N. Total cardiovascular risk assessment and management using two prediction tools, with and without blood cholesterol. MEDICC Review. 2013 [citado 26 nov 2014]; 15(4). Disponible en: http://www.scielosp.org/scielo.php?pid=S1555-79602013000400009&script=sci_arttext

  7. 7.Prugger C, Luc G, Haas B, Morange P, Ferrieres J. Multiple Biomarkers for the Prediction of Ischemic Stroke: The PRIME Study. Arterioscler Thromb Vasc Biol. 2013 [citado 26 nov 2014]; 33(3):659-66. Disponible en: http://atvb.ahajournals.org/content/33/3/659.full.pdf+html

  8. Grau M, Marrugat J. Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. Rev Esp Cardiol. 2008 [citado 7 jul 2012]; 61(4):404-16. Disponible en: http://www.sciencedirect.com/science/article/pii/S0300893208734092

  9. Baena Diez JM, Ramos R, Marrugat J. Capacidad predictiva de las funciones de riesgo cardiovascular: limitaciones y oportunidades. Rev Esp Cardiol Supl. 2009 [citado 7 jul 2013]; 9:4-13. Disponible en: http://www.revespcardiol.org/en/capacidad-predictiva-las-funciones-riesgo/articulo/13146034/

  10. Melander O, Newton Cheh C, Almgren P, Hedbland B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for the prediction of incident cardiovascular events in the community. JAMA. 2009 [citado 11 ene 2013]; 302(1): 49–57. Disponible en: http://jama.jamanetwork.com/article.aspx?articleid=184180

  11. Fàbregas M, Berges I, Fina F, Hermosilla E, Coma E. Effectiveness of an intervention designed to optimize statins use: a primary prevention randomized clinical trial. BMC Family Practice. 2014[citado 26 nov 2014]; 15:135. Disponible en: http://www.biomedcentral.com/content/pdf/1471-2296-15-135.pdf

  12. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 [citado 10 ene 2013] 97: 1837-47. Disponible en: http://circ.ahajournals.org/cgi/content/full/97/18/1837

  13. D'Agostino R, Vasan RM, Pencina MJ, Wolf PA, Cobain M. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation. 2008 [citado 15 feb 2013] 117:743-53. Disponible en: http://circ.ahajournals.org/cgi/content/full/117/6/743

  14. Myers GL, Rifai N, Tracy RP, William R, Wayne A, Biasucci LM, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report from the Laboratory Science Discussion Group. Circulation. 2004 [citado 10 sep 2013] 110(25):545–9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15611379

  15. Brotons C. Mejoremos la predicción del riesgo coronario en España. Rev Esp Cardiol. 2003[citado 10 ene 2014]; 56(3):225-7. Disponible en: http://www.revespcardiol.org/es/mejoremos-prediccion-del-riesgo-coronario/articulo/13043946/

  16. Diener A, Celemín Heinrich S, Wegscheider K, Kolpatzik K, Katrin T. In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study. BMC. Family Practice. 2013 [citado 26 nov 2014]; 14:13. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583804/pdf/1471-2296-14-13.pdf

  17. Cook N, Buring J, Ridker P. The Effect of Including C - reactive protein in Cardiovascular Risk Prediction Models for Women. Ann Intern Med. 2006 [citado 10 ene 2013]; 145(1): 1-19. Disponible en: http://annals.org/article.aspx?articleid=725054

  18. Kennedy E, Wiitala W, Hayward R, Sussman J. Improved cardiovascular risk prediction using nonparametric regression and electronic health record data. Med Care. 2013 [citado 26 nov 2014]; 51(3): 251–8. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081533/pdf/nihms429046.pdf

  19. Marrugat J, Vila J, Baena Diez J, Grau M, Sala J, Ramos R. Validez relativa de la estimación del riesgo cardiovascular a 10 años en una cohorte poblacional del estudio REGICOR. Rev Esp Cardiol. 2011 [citado 15 ago 2013] 64(5):385–94. Disponible en: http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90003647&pident_usuario=0&pcontactid=&pident_revista=25&ty=20&accion=L&origen=elsevier&web=www.revespcardiol.org&lan=es&fichero=25v64n05a90003647pdf001.pdf

  20. Erbel R, Budoff M. Improvement of cardiovascular risk prediction using coronary imaging: subclinical atherosclerosis: the memory of lifetime risk factor exposure. Eur Heart J. 2012 [citado 26 nov 2014]; 33(10): 1201–17. Disponible en: http://eurheartj.oxfordjournals.org/content/33/10/1201.full.pdf+html

  21. Aljutaili M, Becker C, Witt S, Holle R, Leidl L. Should health insurers target prevention of cardiovascular disease?: a cost-effectiveness analysis of an individualized programme in Germany based on routine data. BMC Health Services Research. 2014 [citado 26 nov 2014]; 14:263. Disponible en: http://www.biomedcentral.com/1472-6963/14/263

  22. Batsis J, Lopez Jimenez F. Cardiovascular risk assessment from individual risk prediction to estimation of global risk and change in risk in the population. BMC Medicine. 2010 [citado 2 ene 2013]; 8:29. Disponible en: http://www.biomedcentral.com/1741-7015/8/29

  23. The Emerging Risk Factors Collaboration. C reactive protein, Fibrinogen, and Cardiovascular Disease Prediction. N Engl J Med. 2012 [citado 26 nov 2014]; 367(14): 1310–20. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714101/pdf/nihms488711.pdf

  24. Bacon S, Lavoie K, Arsenault A, Dupuis J, Pilote L, Laurin C, et al. The Research on Endothelial function in Women and men at Risk for cardiovascular Disease (REWARD) Study: Methodology. BMC Cardiovascular Disorders. 2011 [citado 10 ene 2014]; 11:50. Disponible en: http://hinari-gw.who.int/whalecomwww.biomedcentral.com/whalecom0/content/pdf/1471-2261-11-50.pdf

  25. Vega J, Guimará M, Vega L. Riesgo cardiovascular, una herramienta útil para la prevención de las enfermedades cardiovasculares. Rev Cubana Med Gen Integr. 2011[citado 12 dic 2013]; 27(1):91-7. Disponible en: http://scielo.sld.cu/pdf/mgi/v27n1/mgi10111.pdf




2020     |     www.medigraphic.com